Prosecution Insights
Last updated: July 17, 2026
Application No. 18/184,038

PLASTIC COMPOSITION, PLASTICIZER, AND PLASTIC PRODUCT

Non-Final OA §103§112
Filed
Mar 15, 2023
Priority
Apr 12, 2022 — TW 111113899
Examiner
WASHVILLE, JEFFREY D
Art Unit
1766
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Largan Medical Co. Ltd.
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
1004 granted / 1257 resolved
+14.9% vs TC avg
Minimal -5% lift
Without
With
+-4.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
49 currently pending
Career history
1306
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
86.3%
+46.3% vs TC avg
§102
6.5%
-33.5% vs TC avg
§112
3.1%
-36.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1257 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement 2. The information disclosure statement (IDS) submitted on 3/15/2023, 1/12/2024, 9/26/2024, 12/13/2024 and 8/29/2025 were filed timely. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Election/Restrictions 3. Applicant's election with traverse of Group 1 in the reply filed on 5/7/2026 is acknowledged. The traversal is on the ground(s) that no burden is present because of shared technical features. This is not found persuasive because the claims have different claimed structures and therefore create a search and examination burden. Furthermore Applicants have not properly responded to the species requirement. The requirement is still deemed proper and is therefore made FINAL. Claims 13-30 are withdrawn. Claim Rejections - 35 USC § 112 4. Claims 1-14 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. The term “long chain” is not defined properly in the specification and appears to include a single carbon, which would not be long and therefore it is an indefinite descriptor. The term long should be removed and replaced with a definite structure. Claim Rejections - 35 USC § 103 5. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. 6. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 7. Claims 1-12 are rejected under 35 U.S.C. 103 as being unpatentable over (US 5,602,208) to Klamann et al. (hereinafter Klamann) in view of the teachings of (US 2012/0016065 A1) to Sawada et al. (hereinafter Sawada). Klamann is directed toward thermoplastic compositions. Klamann discloses at (C5, L15) that the composition that includes an aminoalkanolamide ester processing aid that may be added to any thermoplastic and blends thereof of polyesters and polycarbonates. PNG media_image1.png 355 427 media_image1.png Greyscale Klamann discloses at (C2, L15) that formula 1 (shown above) reads on Applicants plasticizer formula and (Y), (X) and (Z) respectively and they may contain a double bond or be a straight chain within Applicants , which is therefore biodegradable. Klamann discloses at (C5, L3) that the plasticizer is 0.01 to 10 parts by weight of the resin, which reads on Applicants range of 0.01 to 15%. Klamann discloses a thermoplastic polyester and blends with a polycarbonate, but is silent regarding the use of a PLA. Sawada is directed toward biodegradable polyester thermoplastic compositions. Klamann and Sawada are both directed toward polyester thermoplastic compositions. One skilled in the art would be motivated to use a biodegradable thermoplastic polymer to be environmentally friendly. Sawada teaches at paragraph [0050] that a biodegradable polymer includes polyester, specifically a PLA. Sawada teaches at paragraph [0066] that it is preferable that the biodegradable resin contains a plasticizer. Sawada teaches at paragraph [0060] that the biodegradable resin may include a polycarbonate. The composition is identical and therefore would inherently have the identically claimed rate of degradation. It would be obvious to one skilled in the art at the time of the filing of the disclosure of Klamann in view of the teachings of Sawada to modify Sawada by selecting a PLA as the polyester combined with the plasticizer to have a biodegradable thermoplastic polyester with good molding properties that forms a prime facie case of obviousness for claims 1-12. Conclusion 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEFFREY D WASHVILLE whose telephone number is (571)270-3262. The examiner can normally be reached M-F 9-5. 9. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. 10. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Randy Gulakowski can be reached at 571-272-1302. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. 11. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEFFREY D WASHVILLE/Primary Examiner, Art Unit 1766
Read full office action

Prosecution Timeline

Mar 15, 2023
Application Filed
Oct 21, 2025
Response after Non-Final Action
Jan 30, 2026
Response after Non-Final Action
Jun 23, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679940
LAMINATED FILM AND FLEXIBLE DEVICE
3y 2m to grant Granted Jul 14, 2026
Patent 12674040
NANODIAMOND DISPERSION COMPOSITION
3y 2m to grant Granted Jul 07, 2026
Patent 12667643
SURGICAL ADHESIVES
3y 5m to grant Granted Jun 30, 2026
Patent 12661626
MICROSPHERE SYNTHESIS VIA ULTRASONIC SPRAY PYROLYSIS
3y 7m to grant Granted Jun 23, 2026
Patent 12661872
METHOD FOR MANUFACTURING GLASS SHEET COMPOSITE
3y 2m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
75%
With Interview (-4.9%)
2y 8m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1257 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month